1. Home
  2. GMM vs IVVD Comparison

GMM vs IVVD Comparison

Compare GMM & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.30

Market Cap

39.6M

Sector

N/A

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$2.34

Market Cap

692.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
IVVD
Founded
2017
2020
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.6M
692.7M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GMM
IVVD
Price
$1.30
$2.34
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.33
AVG Volume (30 Days)
16.3K
12.4M
Earning Date
08-18-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$48,171,048.00
$50,039,000.00
Revenue This Year
N/A
$103.88
Revenue Next Year
N/A
$171.40
P/E Ratio
$0.72
N/A
Revenue Growth
41.74
332.71
52 Week Low
$1.23
$0.35
52 Week High
$4.97
$3.07

Technical Indicators

Market Signals
Indicator
GMM
IVVD
Relative Strength Index (RSI) 26.93 54.13
Support Level $1.28 $2.15
Resistance Level $1.41 $2.59
Average True Range (ATR) 0.09 0.17
MACD -0.00 -0.02
Stochastic Oscillator 12.82 50.50

Price Performance

Historical Comparison
GMM
IVVD

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: